BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
Launched by LEIGH R. HOCHBERG, MD, PHD. · Jun 2, 2009
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
The BrainGate2 study is examining a new technology that allows people with limited movement, like those with tetraplegia (when all four limbs are paralyzed), to control a computer cursor and other devices just by thinking about it. This study aims to gather information about how safe this device is and if it works as intended. It's currently looking for participants aged 18 to 80 who have conditions like spinal cord injuries or certain muscle diseases, and they need to live within three hours of the study site.
If you or someone you know is eligible and decides to participate, you can expect to be part of a groundbreaking effort to improve communication and independence for those with severe movement limitations. Participants will have the opportunity to try out this innovative technology and help researchers learn more about its effectiveness. It's important to know that people with certain eye problems or other serious health issues might not be able to join the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of spinal cord injury, brainstem stroke, muscular dystrophy, amyotrophic lateral sclerosis or other motor neuron disorders
- • Complete or incomplete tetraplegia (quadriplegia)
- • Must live within a three-hour drive of the Study site
- • (There are additional inclusion criteria)
- Exclusion Criteria:
- • Visual impairment such that extended viewing of a computer monitor would be difficult even with ordinary corrective lenses
- • Chronic oral or intravenous steroids or immunosuppressive therapy
- • Other serious disease or disorder that could seriously affect ability to participate in the study
- • (There are additional exclusion criteria)
About Leigh R. Hochberg, Md, Phd.
Leigh R. Hochberg, MD, PhD, is a distinguished clinical trial sponsor renowned for his expertise in neurology and biomedical engineering. With a robust academic background and a commitment to advancing therapeutic solutions, Dr. Hochberg leads innovative research initiatives aimed at improving patient outcomes in neurological disorders. His work emphasizes the integration of cutting-edge technologies and clinical practices, fostering collaboration between interdisciplinary teams to drive forward-thinking clinical trials. Dr. Hochberg's leadership is characterized by a dedication to rigorous scientific methodology and a patient-centered approach, positioning him as a pivotal figure in the field of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Atlanta, Georgia, United States
Stanford, California, United States
Sacramento, California, United States
Providence, Rhode Island, United States
Patients applied
Trial Officials
Leigh R Hochberg, M.D., Ph.D.
Principal Investigator
Massachusetts General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials